Belluscura initiates strategic review
By HME News Staff
Updated 9:21 AM CDT, Mon May 12, 2025
LONDON – Belluscura has initiated a strategic review to evaluate a range of options to strengthen its capital position, including potential strategic investment, partnerships and alternative funding structures, following renewed demand for its X-PLOR portable oxygen concentrator in April. “Belluscura remains committed to achieving profitability,” the company stated in a May 9 trading update. “The principal constraint towards achieving this is access to sufficient working capital to fund bulk orders of completed goods, as bulk ordering is a key factor in significantly reducing the unit cost of goods sold.” Belluscura had previously experienced difficulty sourcing product in late February and March, but the company has now confirmed that its POCs, subject to any future regulatory changes, will continue not to be impacted by U.S. import tariffs. Belluscura also says the full commercial launch of the DISCOV-R remains on track for the end of the third quarter. The company says the product will further enhance its offering of next-generation respiratory support devices.
Comments